Can Wegovy Affect Blood Pressure?

Does semaglutide lower blood pressure, and if so, by how much?

The short answer is yes, for most people, and measurably so. In the STEP 1 trial (a 68-week study of 1,961 adults using semaglutide 2.4mg for weight management) participants saw average reductions in systolic blood pressure of around 6 mmHg compared with placebo. That figure comes from the STEP 1 paper published in the New England Journal of Medicine, which remains the primary evidence base for Wegovy's use in weight management.

The mechanism isn't entirely separate from weight loss itself. Carrying less body weight reduces the workload on the heart and vessels, which feeds directly into lower readings over time. If you want to understand how those processes interact, our page on how Wegovy affects blood pressure covers the cardiovascular mechanisms in detail, including what the SELECT trial demonstrated about major cardiovascular events in high-risk adults.

These reductions are clinically relevant. Hypertension is one of the qualifying weight-related conditions under the Wegovy licence, so if high blood pressure brought you to this page, you're in the company of many people for whom that link matters. You can read more about that specific connection on our page covering Wegovy and high blood pressure.

It's worth noting that the blood pressure benefit appears to develop gradually rather than appearing in the first weeks, reflecting the underlying weight loss trajectory rather than any sudden pharmacological effect.

Could Wegovy cause blood pressure to drop too low?

A common assumption is that blood pressure changes on GLP-1 medicines are always about lowering something that's too high. For most people that's broadly true. But a smaller group does experience what clinicians call orthostatic hypotension: a sudden drop in blood pressure on standing that can cause dizziness or light-headedness, usually in the early weeks of treatment or after a dose increase.

This matters most for people who already take antihypertensive medication. As weight falls and blood pressure responds to treatment, their existing prescription may start doing more than it used to, resulting in readings that are lower than intended. It isn't dangerous if it's caught early, but it does mean regular monitoring matters, and your prescriber or GP may suggest reviewing your blood pressure medication as treatment progresses.

Dehydration plays a role here too. Nausea and reduced appetite in the early weeks of semaglutide treatment can mean people drink less without realising it, which compounds any blood pressure dip. Staying well hydrated isn't a minor lifestyle tip in this context, it's genuinely protective. For a fuller picture of how Wegovy interacts with blood pressure across different scenarios, our page on Wegovy and blood pressure covers this in more detail, alongside our page on semaglutide and low blood pressure.

The NHS patient information for semaglutide lists dizziness among reported side effects and advises telling your prescriber if you feel light-headed, particularly when getting up quickly.

What should you tell your prescriber about blood pressure before starting Wegovy?

This is the practical bit, and it doesn't require a lengthy list. Three things matter most.

First, any current blood pressure medication, the name, the dose, and how recently it was last reviewed. As noted above, the picture can shift once weight starts to fall, and your prescriber needs to know what's already in the system. Second, your most recent blood pressure readings if you have them, even from a pharmacy cuff. Baseline data helps a prescriber judge whether changes later are meaningful. Third, any symptoms you've already noticed (even occasional dizziness, particularly on standing) since those can point to blood pressure variability before any treatment starts.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day you submit it. A real clinician looks at your full health history, including cardiovascular conditions, before deciding whether semaglutide is appropriate. That review happens before any prescription is written, not after. If you're considering treatment, the Wegovy treatment page sets out what to expect from the process, and our clinical team can answer questions through aftercare seven days a week.

Blood pressure is also one of the areas where the conversation doesn't stop at the consultation. Ongoing monitoring through treatment is sensible practice, and our prescribers can advise on how often to check and what to do with the readings. For a broader overview of what semaglutide treatment involves, including eligibility and the prescribing process, visit our semaglutide overview.

Does having high blood pressure change who qualifies for Wegovy?

Yes, and in a straightforward way. Wegovy is licensed for adults with a BMI of 30 or above, or for those with a BMI of 27 to 29.9 who have at least one weight-related health condition. Hypertension counts as one of those conditions. So if your BMI sits between 27 and 30 and high blood pressure is part of the picture, that combination can make you eligible for a prescription where BMI alone might not.

The NICE recommendation for semaglutide (TA875) requires treatment to be delivered within a specialist weight management service for NHS patients, alongside multidisciplinary support. Private prescribing through a regulated pharmacy like nume follows the licensed eligibility criteria rather than NICE's service-setting requirements, meaning there's no specialist referral needed and no waiting list.

Lower BMI thresholds apply for people from some ethnic backgrounds under UK clinical guidance, your prescriber can discuss what that means in practice during your consultation. If you're weighing up whether this treatment fits your circumstances, our weight loss treatment overview covers the full picture, and you can check your options directly through a free consultation with our prescribers.